Latest news with #TwistBioscience
Yahoo
23-06-2025
- Business
- Yahoo
Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions
Twist Bioscience Corporation (NASDAQ:TWST) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The firm has expanded its relationship with Element Biosciences to produce end-to-end Next Generation Sequencing (NGS) solutions. A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug discovery. Twist Bioscience Corporation (NASDAQ:TWST)'s library prep and target enrichment workflows are now integrated with Element's AVITI™ devices and Trinity™ flowcells. Twist will be the only supplier of the new Trinity kits for the AVITI platform as a result of the deal. Both businesses will collaborate on commercial efforts to increase customer access to high-performance NGS technologies. The expanded relationship builds on past success, including Twist Bioscience Corporation (NASDAQ:TWST)'s Trinity solution for one-hour quick hybridization. The partnership will improve workflows for agbio, genomics, and clinical research by streamlining hybrid capture both off and on sequencers, according to Twist CEO Emily Leproust. Element Biosciences CEO Molly He highlighted that the combination of Twist Bioscience Corporation (NASDAQ:TWST)'s prep capabilities and Trinity's focused sequencing is essential to advancing science. The partnership will provide researchers with platform flexibility, uniformity, and quality by extending NGS capabilities beyond exome sequencing. While we acknowledge the potential of TWST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif., May 15, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@ Sign in to access your portfolio
Business Wire
15-05-2025
- Business
- Business Wire
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the 'Investor Calendar' page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky
Yahoo
13-05-2025
- Business
- Yahoo
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 13, 2025--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units ("RSUs") and up to 19,379 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4). A portion of the 53,600 RSUs vest over a 48-month period for each employee as follows: 25% vests on the one-year anniversary of the applicable vesting commencement date (the "Vesting Commencement Date"), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee's continued service through each vesting date. A portion of the 53,600 RSUs vest over a 48-month period for each employee as follows: 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date, subject to the employee's continued service through each vesting date. The up to 19,379 PSUs vest on achievement of certain performance metrics set by the Compensation Committee of the Company's Board of Directors, to be achieved by no later than the end of the 2027 fiscal year (which can be earned at 50%-140% of 100% target), subject, in each case, to the employee's continued service through the applicable vesting dates. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker's Stock Picks with Huge Upside Potential
We recently published an article titled . In this article, we are going to take a look at where Twist Bioscience Corporation (NASDAQ:TWST) stands against Nicholas J. Pritzker's other stock picks with huge upside potential. Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners, a San Francisco-based venture capital firm established in 2013. A prominent American entrepreneur and member of the influential Pritzker family, Nicholas Pritzker is widely recognized for his business acumen and leadership within both the family's ventures and his own independent endeavors. He previously served as Chairman and CEO of the Hyatt Development Corporation and is associated with the Pritzker family's substantial business interests, including ownership stakes in Hyatt Hotels and Conwood, a leading chewing tobacco company. His academic journey includes studies at Reed College, Lake Forest College, and the London School of Economics, followed by earning a J.D. from the University of Chicago. At Tao Capital Partners, Pritzker oversees a firm that strategically focuses on investments in technology, transportation, healthcare, education, sustainable food, alternative energy, agriculture, consumer products, real estate, and hospitality. Although he holds the role of chairman, Nicholas Pritzker is not the portfolio manager of the firm. Instead, that position is held by Matthias Brachtel, who is responsible for managing the firm's investment portfolio and making critical financial decisions. Under their leadership, Tao Capital has established a reputation for backing innovative and sustainable ventures, emphasizing long-term positive impacts alongside financial returns. Tao Capital Partners follows a disciplined investment philosophy, targeting sectors poised for growth and transformation. The firm's investments include companies within the technology and transportation industries, as well as those focused on healthcare, education, sustainable food, and clean energy solutions. This diversified approach reflects the firm's commitment to not only achieving financial gains but also fostering advancements in critical global sectors. As of Q4 2024, Tao Capital Partners reported managing $143.28 million in 13F securities across ten core holdings. The firm's commitment to sustainable and impactful investment aligns with Nicholas Pritzker's broader vision of leveraging capital to drive positive change. Pritzker's guidance continues to shape the firm's strategic direction, while Matthias Brachtel's portfolio management expertise ensures the optimization of returns within the chosen sectors. Through a combination of innovative vision and practical financial management, Tao Capital Partners continues to build a diverse portfolio aimed at fostering sustainable growth. For this article, we searched through Tao Capital's Q4 2024 13F filings to identify billionaire Nicholas J. Pritzker's stock picks with the highest upside potential. We compiled the equities with upside potential higher than 2% at the time of writing this article and analyzed why they stood out as sound potential investments. Finally, we ranked the stocks based on the ascending order of their upside potential. To assist readers with more context, we mentioned the hedge fund sentiment around each stock using data from 1,009 hedge funds tracked by Insider Monkey in the fourth quarter of 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug Bioscience Corporation (NASDAQ:TWST) is a biotechnology company specializing in synthetic DNA manufacturing using a proprietary semiconductor-based process. Headquartered in South San Francisco, Twist leverages its high-throughput silicon platform to miniaturize DNA synthesis, offering time and cost savings to its diverse customer base spanning pharmaceuticals, agriculture, and data storage. For the second quarter of fiscal 2025, Twist Bioscience Corporation (NASDAQ:TWST) reported revenue of $92.79 million, surpassing analysts' expectations of $92.00 million. Despite this revenue beat, the company posted a loss of $0.66 per share, missing the consensus estimate of a $0.56 loss. The negative net margin of 59.76% and return on equity of 32.69% reflect ongoing challenges in scaling the business amid high operational costs. Analysts currently forecast a full-year EPS of -2.12. Twist Bioscience Corporation (NASDAQ:TWST)'s market capitalization stands at $2.39 billion, with institutional ownership reaching 112.29%, indicating strong confidence from large investors despite recent financial difficulties. The company's semiconductor-based DNA synthesis technology continues to offer unique advantages, which may support long-term growth as the demand for synthetic biology solutions increases. With a price target of $47.75 and an upside potential of 45.67%, Twist Bioscience Corporation (NASDAQ:TWST) is among billionaire Nicholas J. Pritzker's stock picks with huge upside potential. The company's innovative approach to DNA synthesis and substantial institutional backing position it as a promising player in the biotech space, despite near-term profitability challenges. Overall TWST ranks 2nd among billionaire Nicholas J. Pritzker's stock picks with huge upside potential. While we acknowledge the potential of TWST as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TWST but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires Disclosure: None. This article is originally published at .
